Clinical Trial

Validation of New Biomarkers for Predicting No-Reflow in STEMI Patients Undergoing Primary PCI

Study acronym: VaBiNoR
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
To evaluate the diagnostic value of the selected emerging biomarkers in predicting the no-reflow phenomenon among patients presenting with STEMI undergoing primary PCI. These biomarkers include: HbA1c/C-peptide ratio Albumin-bilirubin (ALBI) score. Neutrophil/HDL ratio
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-17.
Trial Details
NCT Number NCT07132489
Lead Sponsor Assiut University
Conditions Myocardial Infarction, No Reflow Phenomenon
Enrollment 114 participants
Start Date 2025-09-01
Primary Completion 2028-09-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-29